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Background: Pulmonary hypertension (PH) is a serious complication in patients with systemic scleroderma (SSc),
therefore it is important to identify the factors that could predict the presence and progression of PH. Skin biopsy
is performed in patients with SSc to examine the type and severity of the disease. MicroRNAs (miRNAs) are po-
tential biomarkers for various cardiovascular diseases including PH.
Methods and results: We determined the skin miRNA expression proﬁle in 15 SSc patients with (n = 6) and
without PH (n = 9). A mixture of equal amounts of miRNAs from PH and non-PH patients were prepared and
used for miRNA PCR array analysis. The analysis identiﬁed 591 upregulated miRNAs and 57 downregulated
miRNAs in the PH group. Of these, onlymiRNAswith a Ct value of less than 35were subjected to further analysis.
When a 1.5-fold difference was considered meaningful, 32 miRNAs were upregulated and 14 miRNAs were
downregulated in the PH group. Interestingly, 5 out of 14 downregulated miRNAs belonged to the let-7 family.
The resultswere validated by quantitative real-time PCRwith speciﬁc primer for eachmiRNA,which showed sig-
niﬁcant downregulation of ﬁve let-7 familymembers (let-7a, -7d, -7e, -7f, -7g) in 6 PH comparedwith 9 non-PH
skin samples. The expression levels of let-7d and 7b correlated negativelywith pulmonary arterial pressuremea-
sured by echocardiography.
Conclusions: The results suggest that skinmiRNA is a potentially usefulmarker for the presence and severity of PH
in patients with SSc.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pulmonary hypertension (PH) is one of the most serious compli-
cations in patients with systemic scleroderma (SSc). Meta-analysis
indicates that the prevalence of PH is 5 to 14% among SSc patients
[1]. The presence of PH worsens prognosis in these patients [2], and
thus it is important clinically and therapeutically to identify new fac-
tors and biomarkers that can predict the presence and progression of
PH.upported in part by a Grant-in-
Ministry of Education, Science,
ar Medicine, Graduate School of
amoto, 860-8556, Kumamoto,
ya).
eliability and freedom frombias
d Ltd. This is an open access article uA number of clinical factors and biomarkers have been implicated in
SSc-associated PH [3–5]. Recently, much attention has been paid to
microRNAs (miRNAs) as a potential biomarker for PH [6]. miRNA is a
short non-cording RNA known to act as a negative regulator of various
transcription factors [7]. miRNA was originally thought to function
only intracellularly, but recent data suggest that it is also secreted and
detected in the circulation [7]. Various miRNAs have been identiﬁed to
be involved in the pathogenesis of PH [8] and circulating miRNA levels
vary according to the severity of PH [9].
In patients with SSc, skin biopsy is performed to examine the type
and severity of the disease. Although this procedure is not always
required for diagnosis, skin biopsy samples are important to rule out
other ﬁbrosing diseases. We have previously shown that miRNA proﬁl-
ing in skin samples was useful to investigate the functional role of
miRNAs in the development of SSc [10,11]. However, the roles of
miRNAs in the pathogenesis of SSc-associated PH have not been thor-
oughly investigated. In this study, we used skin biopsy samples to test
the hypothesis that skin miRNAs expression proﬁle varies among
patients with SSc and depends on the presence or absence of PH.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics of study participants.
Non-PH group
(n = 9)
PH group
(n = 6)
p
value
Age (years) 73.0 ± 0.8 70.8 ± 4.7 0.59
Females 9 (100%) 6 (100%)
Body mass index (kg/m2) 23.6 ± 1.9 24.0 ± 2.6 0.93
Systolic blood pressure (mm Hg) 147.3 ± 4.8 137.2 ± 9.1 0.50
Diastolic blood pressure (mm Hg) 81.7 ± 2.8 73.2 ± 4.8 0.30
Rheumatic factor 15.1 ± 6.3 21.2 ± 3.0 0.51
Ribonucleoprotein (U/mL) 1.09 ± 0.19 1.06 ± 0.24 0.93
Scl-70 (U/mL) 2.73 ± 0.82 3.54 ± 2.40 0.72
Anti-centromere antibody (U/mL) 97.4 ± 33.8 117.9 ± 40.1 0.71
Brain natriuretic peptide (pg./mL) 36.8 ± 8.6 315.9 ± 121.3 0.01
hs-CRP (mg/dL) 0.07 (0.01–0.24) 0.2 (0.04–0.49) 0.07
Creatinine (mg/dL) 0.55 ± 0.04 0.65 ± 0.06 0.19
eGFR 78.3 ± 4.0 69.2 ± 6.0 0.21
HbA1c (%) 5.8 ± 0.1 5.7 ± 0.1 0.69
LVEF (%) 68.2 ± 0.9 65.5 ± 2.80 0.29
LVDd (mm) 40.2 ± 1.4 38.1 ± 0.7 0.33
Left atrium diameter (mm) 31.6 ± 1.7 34.7 ± 2.6 0.33
E/e′ 11.0 ± 1.4 15.3 ± 4.3 0.28
Pulmonary arterial pressure (mmHg) 27.4 ± 0.87 66.7 ± 7.94 b0.01
Data are mean ± SEM, median (range) or (percentages).
Scl-70, anti-scleroderma antibody; hs-CRP, high-sensitivity C-reactive protein; eGFR, esti-
mated glomerularﬁltration rate; LVEF, left ventricular ejection fraction; LVDd, left ventric-
ular diameter diastolic phase.
Table 2
List of miRNAs with 1.5-folds up- and down-regulation in the PH group.
miRNA ID Fold up-regulation miRNA ID Fold down-regulation
PH(+)/PH(−) PH(+)/PH(−)
hsa-miR-1909* 26.99 hsa-miR-92a −1.57
hsa-miR-221 8.60 hsa-miR-767-5p −1.69
hsa-miR-124 7.30 hsa-miR-370 −1.81
hsa-miR-3173-3p 4.22 hsa-let-7b −1.90
hsa-miR-532-3p 3.49 hsa-miR-628-3p −1.92
hsa-miR-1307 3.29 hsa-let-7d −1.98
hsa-miR-4286 2.60 has-let-7f −2.05
hsa-miR-205 2.55 hsa-miR-433 −2.08
hsa-miR-328 2.48 hsa-miR-23a −2.13
hsa-miR-200c 2.39 hsa-let-7a −2.19
hsa-miR-3647-3p 2.25 hsa-miR-203 −2.39
hsa-miR-200b 2.23 hsa-miR-199a-3p −2.49
hsa-miR-23b 2.08 hsa-let-7 g −2.64
hsa-miR-4301 2.08 hsa-miR-30c −2.77
hsa-miR-3607-5p 2.06
hsa-miR-421 2.04
hsa-miR-24 1.99
hsa-miR-125b 1.91
hsa-miR-125a-5p 1.82
hsa-miR-1247 1.81
hsa-miR-27b 1.79
hsa-miR-490-3p 1.75
hsa-miR-1280 1.67
hsa-miR-365 1.66
hsa-miR-30b 1.65
hsa-miR-1260 1.60
hsa-miR-7-2* 1.60
hsa-miR-720 1.60
hsa-miR-3607-3p 1.59
hsa-let-7c 1.58
hsa-miR-27a 1.51
hsa-miR-126 1.50
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2.1. Study population
Data of 15 SSc patients who underwent skin tissue biopsy were
available for analysis. They were divided into PH (n = 6) and non-PH
groups (n= 9) according to the estimated pulmonary arterial pressure
measured by ultrasound echocardiography (UCG). PH was deﬁned as
tricuspid valve regurgitation pressure gradient (TRPG) of more than
40 mm Hg. The echocardiographic ﬁndings of all study participants
using Aplio XG (Toshiba, Tokyo, Japan) ultrasound systemswere evalu-
ated by two independent investigators whowere blinded to the clinical
data. The clinical and laboratory data reported in this studywere obtain-
ed at the time of skin sampling. The study protocol was approved by the
Human Ethics Review Committee of Kumamoto University and a signed
consent form was obtained from each subject.Fo
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samples.2.2. miRNA isolation, PCR array and real-time PCR
ThemiRNAwas isolated fromhuman skin tissue using themiRNeasy
FFPE kit (Qiagen, Hilden, Germany). For PCR array, themiRNAswere re-
verse transcribed into ﬁrst-strand cDNA using an RT2 miRNA First-
Strand Kit (Qiagen). The cDNA was mixed with QuantiTast SYBR
Green PCR Master Mix, and the mixture was added into 384-well RT2
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Fig. 2. Let-7 family miRNA expression in non-PH (n = 9) and PH (n = 6) groups. Results are mean ± SEM.
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Fig. 3. Negative correlation between let-7 family miRNA expression and tricuspid valve regurgitation pressure gradient (TRPG).
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101Y. Izumiya et al. / IJC Heart & Vasculature 8 (2015) 98–102(Qiagen). For real-time PCR, the primers and templates were mixed
with SYBR Advantage Quantitative PCR Premix (Clontech, Mountain
View, CA). The DNA was ampliﬁed for 40 cycles of denaturation for 5 s
at 95 °C and annealing for 20 s at 60 °C on C1000 Thermal Cycler
(CFX384, Bio-Rad Laboratories, Hercules, CA). The transcript levels
were normalized to those of U6 in the same sample.
2.3. Statistical analysis
Data of two groups were compared for statistical signiﬁcance by the
Student t test. Correlations were assessed by Pearson's correlation coef-
ﬁcient. A p value of b0.05 denoted the presence of a statistically signif-
icant difference.
3. Results
Table 1 shows the clinical characteristics of the study participants.
All participants were female. There was no difference in age, body
mass index, and blood pressure between the PH and non-PH groups.
Auto-immune antibody, renal function, and high-sensitive CRP levels
were not different between the two groups. Plasma BNP level was sig-
niﬁcantly higher in the PH group than in the non-PH group. Left ventric-
ular function and dimension were not different between the two
groups.
For comprehensive evaluation of the skin miRNA expression proﬁle,
we performed miRNA PCR array analysis using a mixture of equal
amounts of miRNAs from 6 PH as well as 6 non-PH skin samples. As
shown in Fig. 1, 591 miRNA were upregulated and 57 miRNAs were
downregulated in the PH group. Of these, only miRNAs with Ct values
less than 35 were considered for further analysis, and 1.5-folds up- or
down-regulated miRNAs were selected. Table 2 lists the selected
miRNAs. The expression of these miRNAs was validated by quantitative
real-time PCR and the results showed signiﬁcant downregulation of let-
7a, 7d, 7e, 7f, 7g in the PH group (Fig. 2).
Next, the correlation between the expression levels of thesemiRNAs
and the estimated pulmonary arterial pressure measured by UCG was
assessed. The expression of let-7b and -7d correlated signiﬁcantly and
negatively with the estimated pulmonary arterial pressure (Fig. 3).
The expression of let-7a, -7e, -7 g, -7f tended to correlate negatively
with the estimated pulmonary arterial pressure, albeit insigniﬁcantly.
4. Discussion
In this study, we demonstrated that the expression level of let-7
family microRNAs in skin was lower in SSc patients with PH than
those without PH. Furthermore, the expression of let-7 family miRNAs
trended to correlate negatively with the estimated pulmonary arterial
pressure. Especially, let-7b and -7d expression levels correlated signiﬁ-
cantly and negatively with the severity of PH in patients with SSc. These
results indicate that skin miRNA levels could be a useful marker for the
presence and severity of PH in patients with SSc.
Skin biopsy is performed even in patients with cardiovascular
diseases to rule out the presence of secondary cardiomyopathies.
Skin tissue biopsy is a less invasive procedure compared with
endomyocardial biopsy, and is recognized as an informative screening
technique for these diseases.We have previously shown that skin biop-
sy is a reliable and safe method for evaluation of amyloid deposition in
patients with cardiac amyloidosis [12]. Similarly, skin miRNA is used as
a biomarker of several skin diseases. For example, miRNA-205 was
down-regulated in patients with dermatoﬁbrosarcoma protuberans
[13]. Another study showed that miR-7 level was signiﬁcantly de-
creased in localized scleroderma [14]. The present study demonstrated
the potential usefulness of skinmiRNA as amarker for the presence and
severity of PH in patients with SSc. Because skin biopsy is performed to
examine the type and severity the disease in patients with collagendiseases, determination of skin miRNA expression level could be an ad-
ditional tool to evaluate disease severity in these patients.
The Let-7 family miRNAs were the ﬁrst discovered human miRNAs
[15]. To our knowledge, there are only three publications on the rela-
tionship between let-7 family and PH [11,16,17]. In these studies, let-7
miRNAs were signiﬁcantly downregulated in lung tissue in an in vivo
model of PH, in vitro smooth muscle cells, and in the sera of patients
with chronic thromboembolic PH. Consistent with these ﬁndings, we
observed low let-7 miRNA expression in skin samples of patients with
SSs-associated PH in this study. The let-7microRNA is known to repress
cell proliferation [18], and knockdown of let-7d enhanced pulmonaryﬁ-
brosis [19]. Therefore, low expression of skin let-7 family in the PH
group could probably reﬂect systemically attenuated anti-ﬁbrotic
properties.
The present study has certain limitations. First, the study included
only a small number of patients recruited at a single center. Further
multicenter studies of larger populations are needed to conﬁrm the
present results. Second, we evaluated PH only by UCG. Right heart
catheterization should be performed for accurate measurement of
pulmonary artery pressure. Third, the present study could not evaluate
the prognostic value of skin let-7 family expression levels due to the
small number of patients enrolled in this study.
5. Conclusion
SkinmiRNA is a potentially useful marker for evaluation of PH in pa-
tients with SSc. Skin biopsy can be considered in patients with collagen
diseases to identify the presence and severity of PH.
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